Associate Director
Alexion
Associate Director
Alexion
Global biopharmaceuticals focusing on rare diseases
This is what you will do:
Associate Director, Nephrology Marketing will responsible to develop and execute Japan aHUS strategy, maximize the business opportunity and deliver outstanding results. And also s/he prepare new pipelines related with nephrology disease area to develop marketing and go-to-market strategies for successful launch in Japan market. This individual must be able to effectively engage, influence, and challenge key internal and external stakeholders to deliver data-driven experiences that effectively advance the business of aHUS and future pipelines related with nephrology. S/he reports into Director, Nephrology Marketing.
You will be responsible for:
You will need to have:
You would prefer for you to have:
Date Posted
28-2月-2025Closing Date
Alexion is proud to be an Equal Employment Opportunity and Affirmative Action employer. We are committed to fostering a culture of belonging where every single person can belong because of their uniqueness. The Company will not make decisions about employment, training, compensation, promotion, and other terms and conditions of employment based on race, color, religion, creed or lack thereof, sex, sexual orientation, age, ancestry, national origin, ethnicity, citizenship status, marital status, pregnancy, (including childbirth, breastfeeding, or related medical conditions), parental status (including adoption or surrogacy), military status, protected veteran status, disability, medical condition, gender identity or expression, genetic information, mental illness or other characteristics protected by law. Alexion provides reasonable accommodations to meet the needs of candidates and employees. To begin an interactive dialogue with Alexion regarding an accommodation, please contact [email protected]. Alexion participates in E-Verify.
Alexion, now the rare disease group within AstraZeneca, develops and sells therapies for rare and ultra-rare diseases by targeting the complement immune system. Its drugs, such as Soliris and Ultomiris, inhibit the C5 component to slow or stop disease processes, while Strensiq and Kanuma address specific metabolic disorders. It differentiates itself through a deep focus on complement biology, pursuing first- or best-in-class therapies, and using a strategy that blends internal R&D with acquisitions to expand its pipeline. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to a broader international market using AstraZeneca’s scale and capabilities.
Explore more opportunities at Alexion